TheraRadar
← Back
Data updated: Mar 29, 2026

CHIA TAI TIANQING

OncologyRespiratoryInfectious Disease
Generics

CHIA TAI TIANQING is a generic drug manufacturer focused on Oncology, Respiratory, Infectious Disease.

2020
Since
3
Drugs
-
Trials
22
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

FULVESTRANT 2025-11-21
Labeling
FULVESTRANT 2025-09-17
Labeling
ERIBULIN MESYLATE 2025-08-05
FOSAPREPITANT DIMEGLUMINE 2025-07-21
Labeling
FOSAPREPITANT DIMEGLUMINE 2025-07-21
Labeling
ERIBULIN MESYLATE 2025-07-03
ERIBULIN MESYLATE 2025-06-09
FOSAPREPITANT DIMEGLUMINE 2025-05-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 73%
2 drugs Phase 3: 23 Phase 2: 25 Phase 1: 63
Respiratory 11%
0 drugs Phase 3: 3 Phase 2: 8 Phase 1: 6
Infectious Disease 5%
0 drugs Phase 2: 5 Phase 1: 5
Immunology 5%
0 drugs Phase 2: 5 Phase 1: 5
Metabolic 5%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 5

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology, Respiratory
Merck big-pharma
Oncology, Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology